SCA
APLS

Secor Capital Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Secor Capital Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,834
Closed -$211K – 26
2019
Q1 		$211K Buy
+10,834
New +$170K 0.04% 360

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Secor Capital Advisors's APLS Position: Q2 2019 in Review

Secor Capital Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2019, closing a stake of 10,834 shares — an estimated $211K sold.

Secor Capital Advisors first reported a position in APLS in Q1 2019 and held it in 1 quarter. The position peaked at $211K in Q1 2019. 99 funds tracked by Wall St. Rank hold APLS as of Q2 2019.

  • Secor Capital Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Secor Capital Advisors sold 10,834 Apellis Pharmaceuticals shares in Q2 2019, an estimated $211K.
  • Secor Capital Advisors first reported a position in Apellis Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Secor Capital Advisors's Apellis Pharmaceuticals position peaked at $211K in Q1 2019.
  • 99 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2019.

Based on Secor Capital Advisors's 13F filing for Q2 2019.